<DOC>
	<DOCNO>NCT00199537</DOCNO>
	<brief_summary>Patients advanced prostate cancer undergo adjuvant treatment androgen blockade follow 1 year interval ass effect treatment bone metabolism . It expect men undergo androgen blockade experience accelerate bone loss .</brief_summary>
	<brief_title>Bone Loss Men Androgen Blockade Adjuvant Therapy Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Men Age 40 year great Diagnosis advance prostate cancer ( ie : prostatespecific antigen [ PSA ] le 25 ug/L undergo continued treatment leuteinizing hormonereleasing hormone [ LHRH ] therapy ) Willing able consent Metastatic disease bone Medications affect bone turnover ( bisphosphonate , steroid , anticonvulsant ) Renal failure ( serum creatinine &gt; 200 umol/L ) Comorbidity factor affect bone density ( ie : Paget 's , rheumatoid arthritis ) Factors affect ability perform bone density test use femoral head measurement ( ie : bilateral hip arthroplasty ) Cancer skin , except , investigator ' opinion , determine appropriate adversely affect outcome trial Gastrointestinal ( GI ) pathology ( eg . malabsorption syndrome ) Parathyroid disease</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>